Newer biologic and small-molecule therapies for inflammatory bowel disease
DC Baumgart, C Le Berre - New England Journal of Medicine, 2021 - Mass Medical Soc
Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …
bowel disease. This review covers newer treatments that reflect our understanding of the …
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
H Nakase, M Uchino, S Shinzaki, M Matsuura… - Journal of …, 2021 - Springer
Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …
selected a panel of 48 experts supported by a team of methodologists and librarians …
ECCO guidelines on therapeutics in Crohn's disease: surgical treatment
M Adamina, S Bonovas, T Raine… - Journal of Crohn's …, 2020 - academic.oup.com
This article is the second in a series of two publications relating to the European Crohn's and
Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's …
Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's …
Tumor necrosis factor inhibitors for inflammatory bowel disease
OH Nielsen, MA Ainsworth - New England Journal of Medicine, 2013 - Mass Medical Soc
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
European Crohn's and Colitis Organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis
[UC] and Crohn's Disease [CD]. For each major class of IBD medications [5 …
[UC] and Crohn's Disease [CD]. For each major class of IBD medications [5 …
One‐year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing
F Castiglione, N Imperatore, A Testa… - Alimentary …, 2019 - Wiley Online Library
Background While mucosal healing has been proved to predict relevant clinical outcomes in
Crohn's disease (CD), little is known about the long‐term significance of transmural healing …
Crohn's disease (CD), little is known about the long‐term significance of transmural healing …
Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease
BL Cohen, DB Sachar - Bmj, 2017 - bmj.com
The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …
Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis
SJ Bots, CE Parker, JF Brandse, M Löwenberg… - BioDrugs, 2021 - Springer
Background and aims Immunogenicity with formation of anti-drug antibodies (ADA) to
biologics is an important reason for treatment failure in inflammatory bowel disease (IBD) …
biologics is an important reason for treatment failure in inflammatory bowel disease (IBD) …
[HTML][HTML] Fibrostenotic strictures in Crohn's disease
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies
followed by anti-integrins and anti-interleukins has drastically changed the treatment …
followed by anti-integrins and anti-interleukins has drastically changed the treatment …